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Twin-screw extrusion, often referred to as Hot-Melt Extrusion within the pharmaceutical 
industry, is an efficient, continuous and solvent-free process that has been investigated extensively 
for its solubility enhancement applications, and, to a lesser degree, for its potential to replace more 
conventional “batch” technologies. The research contained herein focuses on the latter of these 
with attention paid to the effects of screw configuration. In this research, the twin-screw extrusion 
process was utilized to produce taste masked formulations of a BCS I API, which necessitated the 
prevention of amorphous phase formation. The resulting granules were subsequently incorporated 
into an immediate release orally disintegrating tablet (ODT) platform. This processing technology 
was also evaluated as an alternative platform for the production of dry granulations, henceforth 
referred to as Twin-Screw Dry Granulation (TSDG). This novel processing approach was 
investigated using Quality by Design (QbD) principles; however, as the QbD paradigm in product 
oriented, the process was assessed by the successful production of a drug intermediate and, 
ultimately, an optimized target formulation. The TSDG process was utilized to produce a high 
drug loaded sustained release solid oral dosage form in which the crystalline lattice was preserved. 
Moreover, as a fundamental purpose of granulating technologies is the improvement of the 
flowability of one or more of the granule constituents, the resulting granules were assessed for 
enhanced flowability when compared to the very poorly flowing API. Finally, the effects of screw 
configuration on API morphology was evaluated for the effects of system dependence as the 
observed existing literature focuses on single systems wherein the effects of screw configuration 
on API morphology are not assessed for their variations from one carrier system to another. 
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Moreover, the effects of screw configuration were evaluated from the standpoint of the 
preservation of the API crystalline lattice as the observed existing information on screw 
configuration within the pharmaceutical literature focuses on solubility enhancement via 
conversion of the API crystalline lattice into either a molecularly dispersed solid solution or an 
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INTRODUCTION TO EXTRUSION 
 
1.1 Extrusion as a Processing Technology 
Extrusion is a commonly utilized processing technology spanning a wide variety of 
industries including, but not limited to, ceramics, food, metals, paper, plastics, various chemically 
reacted products, and more recently pharmaceuticals [1-10]. In the simplest terms, extrusion is the 
process of forcing material through a die into a material of uniform cross-sectional geometry. The 
ubiquity of this process is owed, in part, to over 100 years of industrial application, as well as the 
numerous variations of the process that are commercially available.  
 
1.2 Types of Extrusion 
While it is important to acknowledge the many subclasses of the extrusion process that 
exist (e.g. direct, indirect, hydrostatic, sheet, forward, backward, blow film, over jacketing, hot, 
cold, etc.), a description and discussion of each is beyond the scope of any single text. Therefore, 
as described within this work there are two fundamental sub-classes of this process that are defined 
by the method in which the in-process material is moved along the barrel and exits the extruder. 
Namely, these are ram extrusion and screw extrusion. While research contained in this work 
focuses exclusively on screw extrusion, which can be further subdivided into single and multi-
screw processes, a brief description of ram extrusion is provided for completeness.   
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1.2.1 Ram Extrusion 
A typical ram type extruder (Figure 1-1) is essentially a piston inside of an extruder barrel 
which, in order to accommodate the forward compressive motion of the piston, is necessarily a 
complimentary shape, typically a cylinder. The piston, when in its retracted position, allows the 
barrel to be filled with the in-process material. In a “hot” process, this material typically remains 
within the extruder barrel until achieving a specified temperature and is then compressed by the 
piston through the extruder die. In contrast, a “cold” process does not require the material to 




1.2.2 Screw Extrusion 
 Screw extruders can be divided into three primary subclasses defined as follows: 
1. Single-screw Extruders: High pressure systems containing only one screw/auger 
within the extruder barrel. 
2. Twin-Screw Extruders: Relatively low-pressure systems containing exactly two 
screws within the extruder barrel. Often further categorized by the relative direction 




of rotation (i.e. counter-rotating & co-rotating) and the degree of intermeshing of 
the screws within the barrel (i.e. intermeshing & non-intermeshing). 
3. Multi-Screw Extruders: Static or rotating center shafts. Further classification can 
be more complex and is typically dependent on the number of screws employed.  
Regardless of the number of screws employed in the process, there are some commonalities across 
the screw extrusion platform. Within each there is a minimum of one screw which is under constant 
torque requirements and is responsible for pumping the in-process materials. To achieve this, a 
standard assembly consisting of the following basic components, or some variation thereof, is 
commonly employed. 
1. Motor (drive unit): provides the required torque to the screw(s)  
2. Barrel: contains the screws and in-process materials;  
3. Die: Attached to the end of the barrel to force the in-process materials into the desired 
geometry. 
 
1.2.3 Single Screw Extrusion 
Single screw extruders (SSE) were the first type of screw enabled extruders to utilize an 
Archimedean type screw for material processing [11]. Single screw extruders are similar in 
function to the previously discussed ram extruders with the primary difference being the presence 
of a rotating screw within the heated barrel (Figure 1-2). The most notable difference is the 
replacement of the ram piston with the continuous rotation of a screw, which provides a clear 
avenue for truly continuous processing as the in-process material is not required to remain stagnant 
until reaching the desired processing temperature. Instead, the feed material is in constant motion 
during the various unit processes (e.g. conveying, plasticizing, melting, devolatization, etc.). The 
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screw’s rotation is powered by a motor, which is typically geared down, thereby reducing the 
motor speed to the desired screw speed (rpm). The gearing is usually housed within a box and 
surrounded by an oil, which serves to lubricate and cool the gears. Single screw type extruders 
function primarily as pumps where the rate of screw rotation provides the forward conveying 
capacity of the in-process material(s). In addition to the heated barrel, the shear imparted to the in-
process material from the rotation of the screw within the barrel provides another source of energy 




Owing to the simplicity of their design, they are also the most commonly utilized type of 
extruder [12]. This type of extruder employs a single one-piece screw which is continuously 
rotated within the extruder barrel. In its simplest form, the screw itself consists of conveying 
sections only. However, various alterations have been employed to improve on this basic design 
thereby enabling enhanced mixing and distributive properties [13]. A SSE is usually characterized 
as a stable high-pressure system capable of consistent output operating in “flood fed” manner 




whose material throughput determined by the revolutions per minute (rpm) of the screw within the 
barrel. It is important to note that a SSE can be operated in a “starve fed” manner, though this 
application is less common. In a starve fed mode of operation, the material throughput becomes 
less dependent on the screw rpm and becomes almost entirely dependent on the introduction of 
new material into the extruder hopper, otherwise referred to as the feed rate.  
Multiple unit operations are achieved within the SSE, such as feeding raw material, downstream 
conveying or the raw materials or polymer melt, melting of the raw materials, devolatization and 
pumping; however, the dispersive and distributive mixing capabilities are generally considered 
inferior to that of their multi-screw counterparts.   
 The screw within a SSE is typically consists of three distinct sections or zones (Figure 1-
3), which can vary in geometry, but are typically defined as Feeding, Transitioning and Metering 
The feed section possesses deeper flights to transport the relatively less dense powder material 
away from the feed throat to subsequent sections. The transitioning section provides gradual 
conversion from the deep flighted feed section, which contains the unmelted pellets or powder, to 




Additionally, the transition section provides the initial compression of the polymer melt prior to 
the metering process. The metering section is the final section in SSE and possesses the shallowest 




flight depth to facilitate a pressure builds in the polymer melt, which in turn functions to facilitate 
extrusion through the die at a consistent rate.  
 While the ratios of the flight to the root of the SSE screw may vary, it ultimately consists 
solely of conveying elements unless otherwise modified. The graphical depiction and 





• Channel Depth: The distance from the tip of the flight to the root 
• Channel Width: The distance between successive flights 
• Trailing Flight: Back edge of the flight 
• Pushing Flight: Front edge of the flight 
• Pitch: The distance required for one full 360o rotation of the flight around the screw root 
• Helix Angle: the angle formed between the flight and a line perpendicular, or normal, to 
the screw root. 
• Screw Diameter (Do): The distance between the furthest flights on a screw root  





• Root Diameter (Di): The distance from the channel bottom on one side of the screw to the 
channel bottom on the other side of the screw.  
• Do/Di: The ratio of the outer diameter to the inner diameter 
The screw itself is typically further characterized by an L/D, or length to diameter ratio. Note that 
the length of the screw in Figure 1-3 is taken to be the entire flighted length of the screw, which 
typically runs from the base near the feeding section to the tip near the die, and the diameter is 
taken to be the screw diameter (Do). The most common ratios used in industry are 25:1 and 40:1, 
though others are common as well.  
 
1.2.4 Twin-Screw Extrusion 
Twin-screw extruders have two screws placed side by side within the barrel of the extruder. 
Functionally, the addition of another screw serves to enhance the compounding ability of the 
process, but at the expense of reduced die pressures. In order to take advantage of this enhanced 
compounding capacity, the barrel of the extruder is often connected to one or more powder, pellet, 
flake, liquid or gas feeding system(s).    
With the addition of the second screw within the extruder, a variety of orientations between 
the screws became possible. The first distinction to draw is the difference between co-rotating and 
counter rotating screws while another distinction is the distance between the screws (i.e. 
intermeshing). Co-rotating screw extruder rotate the screws in the same direction, be it either 
clockwise or counter clockwise with respect to the vantage point of the observer. Counter rotating 
screws rotate in opposing directions, that is, one will rotate clockwise while the other rotates 
counter clockwise.  
8 
 
While extruders with more than two screws are common, it has become apparent that the 
twin-screw extruder has become the extruder of choice within the pharmaceutical industry54. 
Where single screw extruders typically function as continuous pumps, twin-screw extruders 
commonly function as continuous compounders.  
For the purposes of this thesis, further conversation will be limited to the fully intermeshing 
co-rotating parallel twin-screw extruders, henceforth referred to as a twin-screw extruder, hot-melt 
extruder or extruder. This type of extruder has two screws that lie parallel down the length of the 
extruder barrel. They are fully intermeshing, which provides a self-wiping mechanism for more 
efficient processing and decreased material residence times within the extruder. In order to 
facilitate the fully intermeshing corotating mechanics of this process, the additional requirement 
that the twin-screws are of identical configurations with an offset about the screw shaft’s axis is 
necessitated. Interestingly, this simplifies the process setup.   
Where applicable, the extrusion process has numerous inherent advantages over alternative 
processing techniques including relative simplicity, economical design, simplicity of scale-up, 
small processing foot print, reduced processing time and obvious potential continuous processing. 
More recently, this processing technique has been implemented by the pharmaceutical industry.  
Although extrusion itself is generally considered to be a unit operation, where extrudates 
typically go through further downstream processing, it is most easily viewed as a series of sub-
unit operations. Within the context of twin-screw extrusion, these sub-unit operations are, in 
simplest terms, material feeding into the extruder, material conveying and downstream metering, 
melting, mixing, venting, and shaping. Feeding solid or liquid raw materials into the extruder is 
typically accomplished by either gravimetric (weight loss) or volumetric (volume displacement) 
systems.    
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1.2.5 Pharmaceutical Applications of Hot-Melt Extrusion 
Extrusion has attracted considerable attention in the pharmaceutical industry owing to the 
aforementioned reasons. While this process ultimately yields an extrudate of one form or another, 
these intermediate extrudate has been utilized to arrive at a wide variety of dosage forms including 
tablets, pellets, films, implants and granulations [15-26]. In addition to utilizing extrusion as an 
alternative to more conventional technologies present in the pharmaceutical industry, it is also 
being investigated for novel processing approaches. Namely, extrusion has been widely explored 
as a fusion based technique for arriving at the production of solid dispersions.  
The formation of solid dispersions has attracted considerable interest within the 
pharmaceutical industry over recent years. This is due, in part, to the nature of many of the new 
chemical entities (NCEs) currently under investigation. These NCEs are typically arrived at 
through computational chemistry, commonly used to predict the binding affinity of an NCE to a 
biological target, or high throughput screening, which utilizes automated processes to assay the 
biological activity of numerous compounds over a short period of time. Both approaches tend to 
result in compounds that demonstrate exceptional biological characteristics but suffer from poor 
aqueous solubility [27-28]. Unfortunately, the lack of aqueous solubility translates into poor 
bioavailability, which preempts the successful development of viable drug products [27,28]. To 
address the issue of poor aqueous solubility, numerous physicochemical manipulations have been 
investigated including nanoparticle formation [29], various salt forms [30,31], co-crystallizations 
31,32], pre-solubilized formulations [33-35], and API polymorphisms [35,59]. More recently, the 
formation of solid dispersions has attracted substantial attention in both academia and industry.  
Solid dispersions were initially described by Chiou & Riegleman as a solid system in which one 
or more APIs are dispersed into an inert carrier [36]. The carrier itself can exist in an amorphous, 
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crystalline or semi-crystalline (i.e. with both amorphous and crystalline regions) state, while the 
API(s) can be in an amorphous, crystalline or molecularly dispersed state within the carrier. Phase 
separated dispersions can be further categorized into two subclasses, amorphous and crystalline 
dispersions, while the molecularly dispersed API exists as a solid solution. These systems are 
commonly differentiated by their respective thermograms, in which, typical phase transition 
behavior can be identified. A crystalline solid dispersion would typically exhibit a glass transition 
(Tg) for the polymeric carrier and a melting endotherm (TM) for the crystalline API. In contrast, an 
amorphous solid dispersion would typically show a glass transition for each of the amorphous 
components, both the amorphous/semi-crystalline carrier and the amorphous API. A molecular 
level solution would present only a single phase transition for the carrier as the molecularly 
dispersed API would not be subject to any phase changes.  
There are two broadly cited methods of producing solid dispersions, which are solvent 
based systems and fusion based systems. Solvent based methods have historically been utilized to 
arrive at solid dispersions due to their simplicity in concept. First, both the carrier and API are 
dissolved in a common solvent, which is then followed by solvent removal. The rate of solvent 
removal requires consideration with regard to the type of dispersion desired. For example, it is 
generally accepted that rapid removal of the solvent tends to result in either a molecular or 
amorphous dispersion as the intermolecular forces between API molecules are provided 
insufficient time to orient into a crystalline lattice. Lattice formation is further inhibited by the 
presence of the polymeric carrier, which functions by interacting with the API via intermolecular 









THE EFFECTS OF SCREW CONFIGURATION AND POLYMERIC CARRIERS ON 
HOT-MELT EXTRUDED TASTE-MASKED FORMULATIONS INCORPORATED 
INTO ORALLY DISINTEGRATING TABLETS 
 
2.1 Abstract 
The primary aim of this research was to produce successfully taste masked formulations of 
Sildenafil Citrate (SC) using hot-melt extrusion (HME) technology. Multiple screw configurations 
and polymeric carriers were evaluated for their effects on taste masking efficiency, which was 
assessed by both E-tongue analysis and in vitro dissolution in simulated salivary fluid (SSF, pH 
6.8 artificial saliva). The screw configurations were further assessed for their effects on the 
morphology of the API using PXRD, FT-IR and mid-infrared chemical imaging. It was determined 
that the screw configuration had a profound effect on the taste masking efficiency of the 
formulations as a result of altering the physical state of the API. Selected extruded formulations 
using ethylcellulose (EC) with a pore former were further formulated into orally disintegrating 
tablets (ODTs), which were optimized by varying the grade and percentage of the 
superdisintegrant used. An optimized disintegration time of approximately 8 seconds was 
achieved. The final ODT formulation exhibited excellent taste masking properties with over 85% 
drug release in gastric media as well as physical tablet properties. Interestingly, friability, which 
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tends to be a common concern when formulating ODTs, was well within the acceptable limits 
(<1%) for common tablets. 
 
2.2 Introduction 
The perception of taste, or palatability, of a pharmaceutical dosage form is a significant 
concern in terms of patient compliance. The development of successfully taste-masked 
formulations remains to be a particularly formidable challenge when formulating oral dosage 
forms for pediatric populations, who actively refuse to ingest drugs with an unpleasant taste, and/or 
geriatric populations, who tend to exhibit unique perceptions of taste [37,38]. A 2003 survey of 
Pediatricians conducted by the American Association of Pediatrics concluded that the unpleasant 
taste of oral dosage forms was the single greatest obstacle in completing a prescribed therapy due 
to a lack of patient compliance [37]. This problem is further accentuated when attempting to 
formulate orally dissolving/disintegrating platforms (i.e. dissolvable films, orally disintegrating 
tablets, etc.) wherein more traditional methods of taste-masking, such as tablet film coating, are 
not feasible. These rapidly dissolving platforms have received considerable attention as they do 
not require equipment for dosing (oral syringes, measuring cups, etc.), chewing or additional 
liquids in order to be administered. This is because these dosage forms are intended to completely 
dissolve or disintegrate utilizing only the saliva available in the oral cavity. While convenient for 
all populations, this quality makes them ideal for patients who suffer from dysphagia, which is 
common in both pediatric and geriatric populations, where patient compliance is an issue (i.e. 
psychiatric disorders, etc.), or for chronic conditions that are characterized by random and rapid 
onset such as anxiety attacks or migraine headaches [39-44]. Unfortunately, ODTs tend to be 
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relatively fragile and suffer from increased friability which, in turn, leads to more expensive 
packaging requirements. 
Sildenafil Citrate (SC), a phosphodiesterase type 5 inhibitor with a markedly bitter taste, has 
been marketed to both pediatric and geriatric populations as Revatio®, for the treatment of 
pulmonary arterial hypertension, and Viagra®, for the treatment of erectile dysfunction, 
respectively [45-48]. As a BCS I drug, SC presents an additional difficulty in terms of taste 
masking as it readily goes into solution while in the oral cavity thereby allowing it to interact with 
taste receptors more rapidly. Moreover, SC is used to treat the aforementioned chronic conditions 
which necessitate repeated exposure to the drug and excipients used in these formulations. This is 
a particular concern in both pediatric and geriatric populations where a heightened sensitivity to 
even the most modest toxicity may exist [49, 50]. 
Hot-melt extrusion has emerged as a novel and appealing pharmaceutical processing 
technology in recent years [51]. HME processes are characterized by the pumping of raw materials 
along a rotating screw, or screws, inside a barrel at elevated temperatures. The molten material is 
then forced through a die into a substance of uniform shape and character where it is then collected 
for further use [52]. HME is an attractive processing option for pharmaceutical applications as it 
is a potentially continuous process, does not necessitate the use of water or toxic organic solvents, 
is easily scaled up, provides relatively short processing times, and many of the polymeric carriers 
employed during processing are generally recognized as safe [52, 53]. This technology is best 
recognized for its ability to enhance the solubility of poorly water soluble APIs; however, it can 
also be extended to BCS I compounds in which solubility enhancement is not required [54]. This 
application is explored in this research through the modification of screw configurations for the 
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purpose of maintaining the API’s crystallinity while also achieving acceptable homogeneity in the 
extrudates. Here, three configurations and their effects on the physical state of SC are investigated.  
To be suitable for taste masking applications, however, the selected polymeric carrier must 
have two qualities. First, it must inhibit interaction of the API with taste receptors in the mouth. 
Second, it must not appreciably inhibit dissolution in the GI tract. Successful taste masking via 
HME technology would minimize both ensuing processing steps as well as the quantity of flavor 
enhancing excipients required to produce an acceptably palatable end product. In this current 
research, PlasdoneTM S-630 copovidone, AqualonTM N7 ethylcellulose (EC) and multiple grades 
of Klucel™ (HF, EF & ELF) hydroxypropylcellulose (HPC) polymers, were evaluated for their 
effectiveness in taste masking. The most suitable of the polymeric carriers, ethylcellulose, as 
evaluated by taste masking efficiency, was selected for additional experimentation and ultimately 
for formulation into an ODT.  
 
2.3 Materials And Methods 
2.3.1 Materials 
Copovidone (PlasdoneTM S-630), hydroxypropylcellulose (KlucelTM ELF, EF, & HF), 
ethylcellulose (AqualonTM N7), PolyplasdoneTM XL & XL-10 and Sildenafil Citrate were kindly 
gifted by Ashland Specialty Ingredients (Wilmington, DE). Mannitol (PearlitolTM 300-DC) was 
donated by Roquette America Inc. (Keokuk, IA). Sucralose was gifted from JK Sucralose (Jiangsu 
Provence, China).  Monoammonium Glycyrrhizinate (Magnasweet®) was donated by Mafco 
Worldwide CORP. (Camden, NJ). Butylated hydroxytoluene (BHT) was purchased from Sigma-
Aldrich (St. Louis, MO). Magnesium Stearate was purchased from Spectrum Laboratory Products 
Inc. (Gardena, CA.). Calcium carbonate, magnesium oxide, calcium chloride dihydrate, 
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magnesium chloride hexahydrate, sodium chloride, potassium carbonate, sodium phosphate 
dibasic heptahydrate, sodium phosphate monobasic monohydrate as well as all solvents used in 
these studies (analytical grade methanol, acetonitrile & water), were purchased from Fisher 
Scientific (Norcross, GA). Natural & artificial mint flavoring was gifted by Flavors of North 
America (Carol Stream, IL).  
 
2.3.2 Thermogravimetric (TGA) & Differential Scanning Calorimetry (DSC) Analysis 
TGA (Pyris 1 TGA Perkin Elmer) was utilized to determine the thermal stability of the 
individual polymers, BHT, mannitol, magnesium oxide, calcium carbonate and pure SC. Binary 
mixtures (1:1 w/w) of the individual excipients with SC, as well as complete physical mixtures, 
were examined at the temperatures required for melt extrusion processing. During TGA, each of 
the weighed samples was heated from 25oC to 180oC at a rate of 20oC/min. in a platinum pan under 
an inert nitrogen atmosphere purge of 20ml per minute. The samples were held at 180oC for 5 
minutes to simulate the thermal stresses encountered during HME.    
DSC (Diamond DSC, Perkin Elmer) was utilized to confirm the thermal stability of replicate 
TGA samples. The samples, weighing 4-5 mg each, were placed in hermetically sealed aluminum 
pans and placed under an inert nitrogen atmosphere at a purge rate of 20ml per minute. These 
samples were heated from 25oC to 180oC at a rate of 20oC/min., held at 180oC for 5min. and cooled 
to room temperature. The thermograms of the samples were analyzed for deviations from samples 
of the pure substances, as well as for other thermal events. Calibration of the instrument was 





2.3.3 Hot-Melt Extrusion Processing 
Prior to HME processing, the polymers were sieved with a USP #35 mesh screen to remove any 
aggregates that may have formed. The compounds necessary for each physical mixture (Table 2-
1) were placed in a V-shell blender (GlobePharma, Maxiblend®) and mixed at 20 rpm for 20 
minutes. API content uniformity in the physical mixtures was assessed by HPLC analysis using a 
Waters HPLC-UV system (Waters Corp, Milford, MA). A fully intermeshing co-rotating twin-
screw extruder (11 mm Process 11TM, ThermoFisher Scientific) was used to process the physical 
mixtures. The barrel temperature profile and screw speed were based on the physical properties of 
polymeric carrier in each of the preliminary physical mixtures (Table 2-1) and a 3mm rod die was 
attached to the end of the barrel. Three screw configurations were investigated for their effects on 
the physical state of SC post extrusion (Figure 2-1a-c). 
 









Plasdone ® S-630 copovidone 25% 80-110oC 100 
Klucel™ ELF HPC  25% 90-120 oC 100 
Klucel™ EF HPC  25% 90-140 oC 100 
Klucel™ HF HPC  25% 90-160 oC 100 
Aqualon™ N7 EC 25% 90-160 oC 100 
Aqualon™ N7 EC 40% 90-160 oC 100 
Aqualon™ N7 EC + CaCO3 (20%) 20% 140-160





After allowing the extruder to reach a steady state, material was collected from the extruder 
as uniform cylindrical extrudates. The extrudates were allowed to cool to ambient temperature and 
stored in foil lined polyethylene bags for further processing. The extrudates were later milled using 
a comminuting mill (Fitzpatrick, Model L1A). The milled extrudates were sieved to a particles 
size range of 300-425µm using what was retained between US #35 and US #40 sieves. The milled 
and sieved extrudates were stored in glass vials with a foil lined cap for future use.  
 
 
Figures 2-1a-1c: Images of the three screw configurations evaluated during HME process 
optimization. Figure 2-1a: ThermoFisher “Standard Configuration” 40:1 L/D. Figure 2-1b: 
All conveying elements; 40:1 L/D. Figure 2-1c: From Left to Right: 110mm of conveying 
elements; 22mm of perpendicularly arranged mixing elements; 165mm of conveying 





2.3.4 Post-Extrusion Drug Content 
A randomly selected portion of each of the extruded formulations was crushed into a fine 
powder using a mortar & pestle and analyzed for post-extrusion drug content. A known amount of 
the extruded formulations was dissolved in 1:1 methanol:water, diluted with additional 1:1 
methanol:water and filtered using 0.2 µm, 13 mm PTFE membrane filters (Whatman, Piscataway, 
NJ) and analyzed using HPLC analysis. The same method was used to evaluate the finished ODT 
formulations. 
 
2.3.5 High Performance Liquid Chromtography (HPLC) Analysis 
The SC content in dissolution samples was analyzed using a Waters (Waters Corporation, 
Milford, MA, USA) high performance liquid chromatography (HPLC) system equipped with an 
autosampler, UV detector and a Phenomenex® Luna 5µ C18 (150 x 4.6 mm) column. An isocratic 
mode of elution with a mobile phase consisting of acetonitrile and water (60:40) at a flow rate of 
1.0ml/min. was employed to quantify the drug at a wavelength of 273 nm. The data was acquired 
and processed using Waters Empower 3 software suite [55]. 
 
2.3.6 Powder X-Ray Diffraction (PXRD) Analysis   
Powder X-Ray Diffraction (Bruker AXS, Madison, MI) was utilized to determine the 
physical state of SC post extrusion. The X-ray diffraction apparatus used CuKα radiation at 35 mA 






2.3.7 Fourier Transform Infrared (FTIR) Spectroscopy & Mid Infrared Chemical Imaging  
Mid infrared spectral analysis was conducted on an FT-IR bench (Agilent Technologies 
Cary 660, Santa Clara, CA.). The bench was equipped with an ATR (Pike Technologies MIRacle 
ATR, Madison, WI), which was fitted with a single bounce diamond coated ZnSe internal 
reflection element. Chemical imaging was conducted using an infrared microscope (Agilent 
Technologies Cary 620 IR, Santa Clara, CA.) equipped with a 64 x 64 pixel focal plane array 
(FPA) with and without a germanium micro-ATR.  
 
2.3.8 Dissolution Testing of Milled Extrudates 
The milled and sieved extrudates were tested for in vitro drug release in both 150ml of SSF 
(pH 6.8 artificial saliva, Table 2) and 900ml of pH 2 media (0.01N HCl) with USP apparatus I 
(Hanson SR8) at 37 ± 0.5°C with a rotation speed of 100 rpm (n=6) [56, 57]. 
 
2.3.9 Preformulation for Tableting 
Binary (1:1 w/w) mixtures of the milled extrudates with each of the excipients employed 
for tableting, as well as complete physical mixtures representative of the final tablet formulations, 
were stored under accelerated stability conditions (40°C ± 2°C/75% RH ± 5% RH) for one month. 
These samples were then qualitatively analyzed by FT-IR and quantitatively analyzed by HPLC. 
 
2.3.10 Tablet Compression 
Prior to direct tablet compression, the milled extrudates were mixed with mannitol, 
sucralose and Monoammonium Glycyrrhizinate in a V-shell blender at 20 rpm for 20 min. 
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Magnesium Stearate was added during the last 2 minutes of blending. The API content uniformity 
was determined by HPLC analysis. ODTs were prepared on a ten-station Piccola tablet press (SMI) 
using 8.0 mm standard concave tooling and a compression force of 5.5 kN.  
 
2.3.11 Tablet Properties (Friability, Hardness, Disintegration & Weight Variation)  
A dual scooping projection Vanderkamp friabilator (Vankel Industries Inc. Chatham, NJ) 
filled with 22 300mg ODTs in one side, to meet USP requirements, was used to assess tablet 
friability. The friabilator, which rotates at 25 rpm, was allowed to rotate continuously for four 
minutes. The tablets were accurately weighed prior to the test, and carefully de-dusted and 
reweighed after the test. 
Tablet hardness was assessed using a Schleuniger hardness tester. Each tablet tested was placed 
firmly against the stationary anvil prior to beginning the test, and all debris from the previous test 
was carefully removed before performing replicate tests (n=10).  
Weight variation was measured on a microbalance. 20 tablets were weighed, and their 
average determined. The weight of the individual tablets was then compared to the average and 
evaluated within USP specified tolerances for uncoated tablets (± 7.5%). 
Tablet disintegration time was measured on a disintegration tester (Dr. Schleuniger 
Pharmatron). The beakers were filled with one liter simulated salivary fluid (pH 6.8 buffer 
solution, Table 2). The unit was thermally equilibrated to 37 ± 2°C (n=6) prior to tablet 
disintegration testing. Each tube of the apparatus was used to hold one tablet and each tablet was 
covered with a perforated plastic disc. The test was concluded when no particles were retained by 
the 10-mesh in the bottom of each tube. Prior to beginning the test, it was determined that the 




2.3.12 Electronic Tongue Analysis 
The electronic tongue samples were assayed on an Astree e-tongue (Alpha M.O.S.) equipped with 
sensor set #2 (pharmaceutical analysis) composed of seven sets of sensors (ZZ, AB, BA, BB, CA, 
DA, & JE) on a 48 position auto sampler. The individual sample volumes were 25ml and the 
acquisition times were set at 120s. The data generated on the e-tongue was analyzed using principle 
component analysis on the AlphaSoft V12.3 software suite (Mathworks Inc., Massachusetts, 
USA). Each sample was run at least three times, and three replicates of these samples were utilized 
for statistical purposes. The sensors and sample containers were thoroughly cleaned with deionized 
water between each sample assay. The individual assayed samples were diluted for 60 seconds in 
25 ml of phosphate buffer solution (pH 6.8) in order to simulate oral conditions, and the 
supernatant liquid was filtered through 2.5 µm syringe filters.  
 
2.3.13 ODT Oral & Gastric Tablet Dissolution 
In vitro oral drug release was measured using dissolution apparatus I (Hanson SR8) set to 100 rpm 
and equipped with UV-Vis probes (Rainbow Dissolution Monitor, pION) collecting every 5 
seconds for 60 seconds at 273nm. The dissolution medium consisted of SSF (150ml of artificial 
saliva pH 6.8, Table 2-2) and was maintained at 37 ± 0.5°C (n=6). In vitro gastric release was 
evaluated using dissolution apparatus I (Hanson SR8) set to 100 rpm. The dissolution medium 
consisted of 0.01N HCl (900ml) and the temperature was held at 37 ± 0.5°C. Samples were 







Table 2-2. Artificial saliva dissolution media (adjusted to pH 6.8) 









2.3.14 Physical and Chemical Stability 
The final ODT formulations, as well as milled extrudates containing the API, were stored under 
standard (25OC/65% RH) and accelerated (40OC/75% RH) stability conditions for 6 months in 
closed glass containers. The dissolution similarity factor (f2) was utilized to compare the post-
stability dissolution profiles of the ODTs. The milled extrudates were utilized for physical stability 
analysis of the API.    
 
2.3.15 Statistical Analysis of Dissolution Data 
The dissolution data, whether collected using Uv-Vis probes (section 2.2.12), or more 
conventional HPLC analysis (section 2.2.4, 2.2.7 & 2.2.12), were subjected to statistical analysis 
using the Similarity Factor (f2) which allows for an accurate comparison of immediate release 






2.4. Results and Discussion 
2.4.1 Hot-Melt Extrusion & Screw Configuration Selection 
2.4.2 Thermogravimetric & DSC Analysis 
Prior to HME processing, an understanding of the thermal behavior of the API and any employed 
excipients is critical as thermal degradation of the constituents, or an unexpected chemical reaction 
between the constituents, can be thermally induced. The TGA thermograms of the samples were 
observed for changes in weight. The thermograms indicated that the drug, excipients and physical 
mixtures were chemically stable under the thermal conditions that would be employed for HME 
processing as only negligible weight loss near 100oC (<1%), which was attributed to adsorbed 
water, was observed. Thermal degradation of SC occurred at approximately 194oC. DSC data 
supported the findings of TGA analysis as no unexpected thermal events were observed under the 
same conditions. It was concluded that the temperatures necessary to process the carriers were 
suitable to employ. Thermal degradation of SC was observed to occur with the onset of melting at 
approximately 194oC. The simultaneous melting and decomposition of SC has been previously 
reported and is recognized as thermally induced dissociation of Sildenafil base and citrate wherein 
citrate is responsible for the observed degradation [58].  
 
2.4.3 Polymer Screening 
Binary Mixtures of the individual polymers with SC were extruded and evaluated for in vitro drug 
release in artificial salivary fluid (Figure 2). While each of the polymers that was investigated 
showed promising taste masking potential during preliminary screening at up to one minute, the 
subsequent accelerated release exhibited by Plasdone S-630 was a source of concern. A 
comparison the S-630 dissolution profile with 25% and 40% drug loaded ethylcellulose 
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demonstrated a significant difference in terms of similarity factors (f2 = 20 & 36, respectively).  It 
was, therefore, removed from further consideration. Relative to ethylcellulose, the HPCs (grades 
HF, EF and ELF), too, showed a heightened, but steady, release (f2 = 45, 42 & 39, respectively, 
when compared to 25% drug loaded ethylcellulose). It was concluded that the initial in vitro drug 
release studies of the various carriers indicated that ethylcellulose, with 0.2% BHT as an 
antioxidant, provided the greatest taste masking potential and was selected for additional study. A 
comparison of two drug loadings (25% & 40%) in ethylcellulose was evaluated (Figure 2-2). At 
1.5 minutes of oral dissolution the 40% drug load showed more rapid dissolution (approximately 
5%). This finding was not statistically significant when the profiles were compared using the 
similarity factor (f2 = 71). The lower drug loading (25% API), which was suitable for the targeted 
dose of SC, was selected for additional study.  
 
 
Figure 2-2: SC release profile of preliminary polymer screening formulations in artificial 


















75% S-630, 25% Sildenafil
75% EC-N7, 25% Sildenafil
75% HPC HF, 25% Sildenafil
75% HPC EF, 25% Sildenafil
75% HPC ELF, 25% Sildenafil
60% EC-N7, 40% Sildenafil




2.4.4 PXRD Analysis 
X-Ray diffraction was used to examine the effects of the three screw configurations on the physical 
state of SC in the carrier post-extrusion. Figure 3a shows the diffractogram for pure SC for 
comparison with the extruded formulations. The effect of the three screw configurations on the 
physical state of SC was considerable. The screw configuration in Figure 2-1a (ThermoFisher 
Standard Screw configuration; 40:1 L/D) resulted in highly amorphous phase SC, which was both 
unnecessary and undesirable in the case of a BCS I API and was, therefore, not utilized for future 
processing. The amorphous form, being more readily soluble, would only serve to hinder any taste 
masking effects imparted by the carrier. Additionally, the amorphous form of an API is inherently 
less thermodynamically stable and, consequently, subject to recrystallization into various 
polymorphs, which have differing physical properties, if they exist [59]. This observed conversion 
was attributed to not only the length of the screw, and thus increased residence time in the extruder, 
but more significantly, the presence of three high shear mixing zones which, depending on 
configuration, are primarily responsible for the conversion of crystalline phases of an API to their 






Figures 2-3a-b: a; PXRD diffractogram of pure crystalline SC. b; PXRD diffractograms of 
binary mixtures of ethylcellulose & SC as a function of screw configurations.  
 
The screw configuration in Figure 1b preserved a considerable portion of the crystalline phase 
of the API; however, there remained noticeable amorphicity of SC in the carrier as depicted in 







































flight of conveying elements and the barrel of the extruder was responsible for the amorphicity 
noted in the diffractogram. Screw design 3 (Figure 2-1c) was designed to be shorter than the 
previous two (25:1 L/D) while still imparting sufficient distributive mixing to the melt. Indeed, 
despite the employment of a single mixing section in Figure 1c, in which the mixing elements were 
perpendicularly arranged, the diffractogram for screw configuration 3 showed enhanced 
preservation of the crystalline structure of SC in the carrier matrix as can be seen in the 
diffractogram.  
 
2.4.5 FT-IR & Mid Infrared Chemical Imaging 
Mid-infrared (MIR) spectra of crystalline and amorphous SC were collected and compared. 
Differences in these MIR infrared spectra allowed for differentiation between the phases in the 
extruded material. This was accomplished using a series of spectral derivatives to exploit the 
differences highlighted in the spectra (Figure 2-4). It has been previously reported that the unbound 
carbonyl, located at 1697cm-1 in the more organized crystalline structure, becomes shifted when it 
is free as is the case with Sildenafil base [58].  
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Figure 2-4: FTIR spectra of crystalline and amorphous SC. 
 
Additionally, virtually all of the intermolecular bonding is attributed to interaction between COOH 
groups in the citrate portion and the carbonyl and the amine group, which appears at 3294cm-1 in 
the crystalline form, and is shifted to 3307cm-1 in the amorphous form. The sulfone group, which 
appears at 1171cm-1 in the crystalline form has shifted to 1164cm-1 in the amorphous form. In this 
study, the amorphous form of SC was produced using the well-known solvent evaporation 
technique. The infrared images (Figures 5a-c) were produced by taking spectral derivatives of the 
obtained spectra and isolating spectral bands representative of the crystalline phase alone. The 
amorphous phase carbonyl center is shifted to 1692cm-1 as opposed to 1697cm-1 in the crystalline 
phase.  
Figures 2-5a represents an infrared image of crystalline SC in the polymer matrix, post 
extrusion using screw configuration 2 (Figure 2-1b), taken at 5.5 µm spatial resolution in 
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a lack of crystalline API due to either complete absence of SC or the presence of the amorphous 
phase. This seems to correspond well with XRD data and analysis of the same material. 
Figure 2-5b, representative of screw configuration 3 (Figure 2-1c), illustrates a more uniform 
distribution of crystalline SC in the carrier. Here it can be seen that there exists good homogeneity 
of SC in the polymeric carrier as indicated by the relatively modest intensity of the carbonyl 
centered at 1697 cm-1 that this image is taken with respect to. Additionally, the pockets of 
crystallinity are less apparent at this spatial resolution. However, Figure 5c represents an infrared 
image taken with a Ge micro ATR at 1.1 µm spatial resolution with a total FOV of 70 x 70 µm. 
On closer inspection, it is apparent that there is a slight inhomogeneity of SC in the carrier as the 
low intensity blue areas correspond to a complete lack of crystalline SC in that region. 
Additionally, the elevated yellow and regions in the images correspond to pockets of crystalline 
SC. These small pockets of inhomogeneity are presumably due to preserving the crystalline 
structure of SC. Interestingly, this inhomogeneity showed no effect during content uniformity 
testing by HPLC analysis and was, therefore, considered negligible. This was presumed to be due 






Figure 2-5a-c: Chemical image (5.5 µm spatial resolution) of a binary mixture of 
ethylcellulose & SC highlighting the intensity of the carbonyl present in crystalline SC 
processed using screw configuration 2 (Figure 2-1b). Figure 5b: Chemical image (5.5 µm 
spatial resolution) of a binary mixture of ethylcellulose & SC highlighting the intensity of the 






Figure 2-5c: Chemical image (1.1 µm spatial resolution) of a binary mixture of ethylcellulose 
& SC highlighting the intensity of the carbonyl present in crystalline SC processed using 
screw configuration 3 (Figure 2-1c). 
 
3.1.5 E-Tongue & Oral Dissolution Testing of Milled Extrudates 
Electronic tongue evaluation and in vitro dissolution of the milled extrudates, which consisted of 
20% SC loading in ethylcellulose, on the basis of screw configuration supported the physical 
characterization studies (FT-IR & XRD). The distance chart (Figure 2-6) graphically illustrates the 
principal component analysis results taken as a comparison of the reference or blank (artificial 
saliva solution).  
 
 
Figure 2-6: Graphical illustration of PCA results from e-tongue analysis illustrating each 






















Screw Configuration E-Tongue Evaluation Chart
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Here it is presumed that the greater the distance to the blank, the less efficient the screw 
configuration is for taste masking purposes. It can be seen that pure SC and the physical mixture 
are poorly taste masked as they exhibit the greatest distance from the blank, as would be expected. 
Screw configuration 1 also produced a poorly taste masked product due to the conversion of the 
crystalline lattice of SC to the amorphous form, which goes into solution more rapidly.  
Screw configurations 2 & 3 produced comparable results on the basis of e tongue and in vitro 
oral dissolution (Figure 2-7); however, the results were not in complete agreement. E-tongue 
analysis indicated that screw configuration 3 produced a superior taste masked product, which was 
attributed to improved encapsulation of SC in the polymeric carrier. Additionally, FT-IR analysis 
indicated that the crystalline lattice was more effectively preserved when employing this 
configuration, which further explains the differences in e-tongue analysis. On the other hand, the 
dissolution data indicated screw configuration 2 produced a slightly better product in terms of taste 
masking. 
 






















In Vitro Release in Artificial Saliva (pH 6.8)
Screw Design 1 Screw Design 2 Screw Design 3 Physical Mixture
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Upon closer examination of the dissolution profiles for these screw configurations at 30 
seconds, which is the maximum amount of time the formulation is expected to remain in the oral 
cavity, there exists a negligible difference (<1%) between the two profiles, which was further 
supported by the similarity factor comparison (f2 = 73). These observations along with the physical 
characterization data, wherein it was shown that screw configuration 3 produced a more uniform 
crystalline dispersion, aided in deciding that screw configuration 3 would be utilized for further 
processing. Interestingly, there seems to exist a strong correlation between the e-tongue analysis, 
wherein greater distance would be indicative of greater interaction of the API with the taste 
sensors, and dissolution data, which indicates the amount of API in solution available for the 
perception of taste.  
 
2.4.7 Addition of Release Modifying Agents 
While ethylcellulose, an erodible polymer, was selected due to a very low release profile in 
artificial saliva, it became necessary to incorporate a release modifying agent for more rapid drug 
diffusion as gastric drug release was correspondingly low. Magnesium oxide and calcium 
carbonate were selected as potential pore formers due to being practically insoluble near salivary 
pH while being completely soluble at or near gastric pH. Mannitol was also used as a pH 
independent pore former. Additionally, it was postulated that any dissolution of mannitol in the 
oral cavity could have potentially served as an additional taste masking agent as a result of being 
a sugar alcohol with a sweet flavor.  
Initial e-tongue screening of the individual pore formers within the extruded matrices (20% each) 
demonstrated promising results (Figure 2-8) for both magnesium oxide and calcium carbonate. 
However, magnesium oxide produced highly erratic results during gastric dissolution screening 
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and was therefore removed from consideration for further taste masking application. Based on the 
distance chart results for the pore formers, mannitol was also excluded from further consideration. 
It was observed that the quantity of mannitol needed for adequate pore forming capacity was 
assisting in solubilizing SC during the melt extrusion processing, which hindered the taste masking 
capacity of the formulations. This observation explains why mannitol ranked very closely to pure 
SC during the e-tongue analysis.  
 
 
Figure 2-8: Graphical illustration of PCA results from e-tongue analysis illustrating each 
samples distance from artificial salivary fluid as a function of individual pore former in each 
formulation.  
 
Oral dissolution data for calcium carbonate agreed well with the e-tongue results (Figure 2-


























as hypothesized as calcium carbonate is insoluble near neutral pH, which should prevent the 
formation of diffusion promoting pores, thus keeping the exterior of the matrix intact. Because of 
these observations, calcium carbonate as the pore former was selected for additional studies.  
 
 
Figure 2-9: Dissolution release profile of milled extrudate (20% SC, 60% ethylcellulose & 
20% calcium carbonate) in artificial salivary media (pH 6.8). 
 
2.4.8 Tableting API-Excipient Compatibility 
After storage for one month under accelerated stability conditions (40oC/75% RH), HPLC analysis 
was conducted to evaluate the compatibility of the extruded formulations with the excipients 
selected for direct compression tableting (Table 2-3). All API-excipient compatibility samples 
were dried in the presence of desiccant prior to investigation in order to remove adsorbed water 
which would interfere with both qualitative spectral analysis and quantitative chromatographic 
























In vitro Oral Release With CaCO3 in 





wherein the spectra were observed for the appearance and/or disappearance of previously 
unobserved characteristics. When no changes in the infrared spectra were observed, these samples 
were further evaluated quantitatively using HPLC analysis. No incompatibilities were noted. 
 
Table 2-3. ODT formulation including the varying percentages of super disintegrant and 
filler used 
Constituents Concentration 
PVP (Grades XL & XL-10) 2.5, 5 & 10% 
Sucralose 1% 
Magnasweet 1% 
Nat. & Art. Mint Flavor 1% 
Milled Extrudate 41.7% (Equivalent to 25mg of SC) 
Mannitol (300DC) 52.3, 49.8 & 44.8% 
Magnesium Stearate 0.5% 
 
 
2.4.9 Tablet Properties 
Tablets containing varying levels of super disintegrant (PVP XL & XL-10) were evaluated for 
common tablet properties (Tables 4a & 4b respectively). The percentage of super disintegrant 
evaluated ranged from 2.5-10. As noted earlier, friability tends to be a common concern when 
formulating ODT platforms. To the contrary, these formulations exhibited excellent friability (0.8-
0.32) despite having somewhat low hardness values (2.68-6.56 kp). The low hardness values are 
attributed to the poor compressibility and high loading (41.7%) of the milled extrudates in the 
ODT formulations. Interestingly, the disintegration times for the ODTs were within the acceptable 
limits for ODT designation (approximately 8-33 seconds depending on formulation), which are 
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generally taken to be less than 30 seconds. While the tablets formulated with PVP XL-10 
demonstrated improved hardness and friability values, those formulated with PVP XL 
demonstrated superior disintegration times, which is a primary concern when formulating rapidly 
dissolving platforms. Remarkably, tablets containing 5.0% PVP XL had average disintegration 
times of 8.6 seconds. With the other properties within the acceptable ranges, priority was given to 
disintegration time. Therefore, ODTs containing 5.0% PVP XL were selected for oral and gastric 
dissolution studies. 
 
Table 2-4(a). Tablet properties as a function of the percentage of PVP XL incorporated 
 2.5% PVP XL 5.0% PVP XL 10% PVP XL 
Disintegration Time (sec.) 11.3±1.01 8.6±0.62 9.3±1.63 
Percent Friability 0.24±0.01 0.32±0.02 0.19±0.01 
Thickness (mm) 4.63±0.06 4.63±0.05 4.67±0.01 
Hardness (kp) 3.57±0.64 2.67±0.30 2.89±0.55 
Loss on Drying (w/w) 2.22±0.46 2.37±0.42 2.66±0.63 
 
Table 2-4(b). Tablet properties as a function of the percentage of PVP XL 10 incorporated 
 2.5% PVP XL-10 5.0% PVP XL-10 10% PVP XL-10 
Disintegration Time (sec.) 33.3±5.10 27.7±2.71 30.0±3.99 
Percent Friability 0.08±0.02 0.23±0.001 0.13±0.01 
Thickness (mm) 4.64±0.02 4.63±0.09 4.66±0.14 
Hardness (kp) 6.56±0.50 5.68±0.31 5.90±0.48 
Loss on Drying (w/w) 2.17±3.00 2.34±0.20 2.61±0.52 
 
 
2.4.10 ODT Oral & Gastric Tablet Dissolution 
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Oral and gastric dissolution profiles (Figures 2-10a-b) were evaluated for finished product (ODT 
containing 5% PVP XL) drug release. While the oral dissolution study was conducted for 60 
seconds, a disintegration time of approximately 8 seconds indicates that the formulation would 
remain in the oral cavity for 30 seconds or less. At this time, the tablets exhibited a mere 2% drug 
release. The gastric release profile of the tablets indicates that excellent release can be obtained by 
incorporating the milled extrudates into rapidly dissolving platforms. In this case, more than 80% 

















Figure 2-10a: Dissolution profile of optimized SC ODT formulation in artificial salivary 
fluid (pH 6.8) 
 
 
















































Gastric Release (0.01N HCl)
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2.4.11 Physical and Chemical Stability 
The milled extrudates were assessed for physical stability of the API by both FT-IR and PXRD 
analysis. There was no observable difference in the spectra generated by either method indicating 
that that the specific polymorphic crystalline lattice had been preserved after both standard and 
accelerated stability testing, as would be expected. The milled extrudates were also assessed for 
chemical stability by HPLC analysis using the method outline in section 2.2.4, and their similarity 





In this study, HME was successfully employed as a processing technology for the production of 
taste masked formulations containing SC. This was accomplished by embedding the API in 
ethylcellulose along with a pH dependent pore former. The crystallinity of SC, and presumably 
the subsequent physical stability, was found to be dependent on the screw configuration and pore 
former used. FT-IR spectroscopic imaging, in tandem with conventional XRD analysis, proved to 
be very valuable in the evaluation of the melt-extruded formulations as it was demonstrated that 
preserving the crystalline structure of SC was critical for arriving at successfully taste masked 
formulations.  The addition of calcium carbonate into the extruded formulations proved to be 
especially advantageous in that its pH dependent solubility helped prevent drug dissolution under 
oral conditions (pH 6.8) while promoting drug dissolution under gastric conditions (pH 2). The 
ODT formulations demonstrated uncharacteristic but excellent friability profiles without 
sacrificing disintegration time, which is critical for ODT formulations. E-tongue assessment of 
taste masking efficiency, in conjunction with dissolution data, was found to be extremely valuable 














A QUALITY BY DESIGN INVESTIGATION OF A NOVEL TWIN-SCREW DRY 
GARANULATION PROCESS 
3.1 Introduction 
Historically, extrusion processes have found considerable applicability in a multitude of 
processing fields. A few examples might include metal & plastic profile extrusion, ceramic 
extrusion, cooking & confectionary extrusion, plastic & rubber compounding extrusion, polymer 
synthesis reaction extrusion, and finally, with over a century of industrial refinement, 
pharmaceutical extrusion [1-11]. The extrusion processing platform, be it ram, single or multi-
screw, has a sound reputation for being economical, efficient, continuous and, most importantly, 
consistently reliable for the repeated production of high quality products. The later of these 
qualities, being a source of ill repute and vulnerability for the pharmaceutical industry as evidenced 
by the ubiquity of drug recalls, has led to the FDA’s substantial push for QbD guided process 
development [60, 61]. While most of the primary requirements for developing a QbD based process 
are conceptual in nature (QTPP, FMEA, DoE), and thus easily implemented in a wide array of 
processes, those required by the enhanced QbD requirements, namely in-line process monitoring 
and process controls, are relatively foreign to conventional pharmaceutical processing 
technologies. By contrast, these in-process analytics and controls are not only integrated into 
extrusion systems, but are also fundamental to the process.    
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Twin-screw extrusion has attracted considerable attention in the pharmaceutical industry as an 
alternative processing technology where bioavailability enhancement is required and multiple 
review articles cover this application aspect in detail [62-65]. More recently, the innumerable 
advantages inherent to extrusion processing (economical processing, small scale-up footprint, 
reduced in-process times, solvent free/green processing, reduced processing steps, continuous 
processing, etc.) have led to applicability studies where solubility enhancement is either not 
required, undesirable or where this processing technology simply imparts its advantages over more 
conventional processing platforms. Indeed, investigations in twin-screw granulation processes are 
rapidly increasing, and for good reason [66-83].  With approximately 70 percent of 
pharmaceuticals being solid dosage forms, and the primary physical modification of the bulk 
ingredients being a granulation process of one form or another, any advancement in granulation 
technology is going to have significant implications [84]. 
Granulation processes are commonly employed in the pharmaceutical industry as a means to 
increase particle size, reduce segregation, improve flowability and enhance compressibility. Dry 
granulations are often considered useful for formulations that have acceptable compression 
properties, but suffer from poor flowability. Unlike wet granulations, dry granulations do not 
require the formation of a wet mass along with the subsequently necessary drying operations, and 
are also suitable for hydrolysable compounds. Typically, a dry granulation process consists of the 
addition of mechanical energy to a formulation containing a dry binder. The resulting 
agglomerated mass is then often subjected to one or more milling, sieving and blending operations.  
The primary objective of this work was to investigate the previously unreported utility of 
a fully intermeshing, co-rotating, twin-screw extruder for the development of a Twin-Screw Dry 
Granulation (TSDG) process. TSDG fundamentally differs from the more conventional 
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pharmaceutical applications of twin-screw extruders (i.e. Hot-Melt Extrusion; HME) in that the 
formulation’s constituents are not processed into a continuous melt within the barrel, but are 
instead compacted into discrete agglomerates. In further contrast to HME processes, wherein the 
in-process melt functions as the lubricant for the barrel and rotating screws, an additional powder 
lubricant was required to prevent the observed metal on metal contact during TSDG processing. 
The TSDG process differs substantially from its wet granulation counterpart as well in that no 
solvents or binder solutions are required. This is particularly advantageous in that the need for 
subsequent, and often lengthy, drying operations is circumvented along with analytical 
determinations of residual organic solvents when used. Moreover, this dry processing approach 
does not preclude the incorporation of hydrolytically sensitive actives or excipients. Careful 
attention to screw design was required as there existed a balance between simply pushing the 
powdered formulation through the extruder (powder in-powder out), the formation of melted 
material and the formation of a dry granulated material.  
A Quality by Design approach was implemented in order to arrive at a well-defined process 
yielding a product of predefined character and quality. In this case study, Sildenafil Citrate, a BCS 
class I API, was utilized as a model drug for the granulating process. The selection of this API was 
beneficial in that it exhibits poor flowability, which makes it ideal for a granulating process 
wherein high drug loading is desired. Additionally, a BCS I API poses the possible challenge of 
undesirable amorphous phase formation, an application for which twin-screw extruder processing 
is both well-known and suited.  
The objectives outlined in the quality target product profile (QTPP) were to produce a high 
drug loaded, sustained release formulation in which the API’s pre-existing crystalline lattice was 
preserved (Table 1). The resulting granules were assessed for surface morphology, API phase 
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changes, chemical interactions, conventional granule properties (i.e. compressibility index, angle 
of repose, Hausner ratio), and finally utilized to produce a high drug loaded sustained release solid 
oral dosage form.  
 
Table 3-1: Quality Target Product Profile (QTPP) 
QTPP Element Target Justification 
Dosage form Tablet Pharmaceutical equivalence requirement: 
same dosage form 
Route of administration Oral Pharmaceutical equivalence requirement: 
same route of administration 
Dosage strength 100 mg 
 
Pharmacokinetics In vitro dissolution – 12-18hrs 
80% release 
 
Stability At least 6 months 40C/75RH 
accelerated stability 
 
Drug Product quality 
attributes 
Physical Attributes Tablets (size, color, shape)  
Identification Positive identification for sildenafil citrate 
Assay 90.0-110.0 (Compendial requirement) 
Content Uniformity AV < 15.0 (USP<905>) 
Degradation Products Monitor and report (CQA) 
DSC Monitor and report (CQA) 
TGA Monitor and report (CQA) 
XRPD Monitor and report (CQA) 
NIR Monitor and report (CQA) 
Residual Solvents Will not be monitored for this study 
Drug Release Extended Release 
Microbial Limits Will not be monitored for this study 
Water Content Will not be monitored for this study 
Container Closure System NA 
 
Administration/concurrence 
with labeling NA 
 




3.2 Materials & Methods 
Hydroxyethyl cellulose (NatrasolTM 250 L), ethyl cellulose (AqualonTM N7), hydroxypropyl 
cellulose (KlucelTM HF) and Sildenafil Citrate were generously donated by Ashland Specialty 
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Ingredients (Wilmington, DE). Magnesium Stearate, hydrochloric acid and the solvents used in 




3.3.1 API-Excipient Compatibility 
Binary (1:1 w/w) mixtures of the API with each of the excipients, as well as complete physical 
mixtures representative of the final tablet formulations, were stored under accelerated stability 
conditions (40°C ± 2°C/75% RH ± 5% RH) for one month. These samples were then analyzed by 
FT-IR spectroscopy.   
 
3.3.2 Fourier Transform Infrared Spectroscopy (FT-IR) 
Mid infrared spectral collection was performed on an FT-IR bench (Agilent Technologies Cary 
660, Santa Clara, CA.). The bench was equipped with an ATR (Pike Technologies MIRacle ATR, 
Madison, WI), which was fitted with a single bounce diamond coated ZnSe internal reflection 
element. The spectra were collected over a range of 4000-650cm-1. Spectral analysis was 
conducted using the Resolutions Pro software suite (Agilent Technologies, CA.). 
 
3.3.3 Preliminary Range Screening of Formulation & Process Variables 
Prior to a formal DoE, preliminary studies were conducted to evaluate acceptable process 
parameter ranges (e.g. screw configurations, screw speeds, feed rates, etc.) and formulation 





3.3.4 Experimental Designs (DoE) & Analysis 
Experimental designs were created and evaluated using DoE software (StatEase, Design-Expert® 
Version 8.0.6, Minneapolis, MN). A fractional factorial design (Min Run Res IV) with two center 
points was used as a screening design for the elucidation of main effects, which resulted in a total 
of 16 experimental runs. A full factorial 2 level (23) with four center points was utilized to evaluate 
interactions between the previously selected main effects and curvature present within the design. 
The full factorial design necessitated an additional 12 experimental runs. Finally, the results from 
the full factorial design were used to produce contour plots, response surface plots, and to predict 
an optimized formulation and process.   
 
3.3.5 Physical Mixture Preparation 
Prior to TSDG processing, the polymers were sieved using a USP #35 (500 µm) mesh screen to 
remove any aggregates that may have formed. The components necessary for each physical 
mixture were geometrically diluted using a glass mortar and pestle.  
 
3.3.6 Twin-Screw Dry Granulation (TSDG) 
A fully intermeshing, co-rotating, twin-screw extruder (11mm Process 11TM, ThermoFisher 
Scientific) was used to process the physical mixtures. The extruder experiments were conducted 
without a die on the extruder barrel. After allowing the extruder to reach a steady state, material 
was collected from the extruder in the form of granules and/or fine powder. The granules were 





3.3.7 Scanning Electron Microscopy (SEM) 
SEM was used to assess the surface morphology of the final optimized formulation in three 
different forms. These were the physical mixture, a representative melt extruded sample, and the 
optimized dry granulated sample. Prior to sample mounting, the surfaces of the samples was cut 
with a razor in order to provide a flat surface to focus upon. Adhesive carbon tape was used to 
mount the samples onto an aluminum stage. These samples were then sputter coated with gold 
under an argon atmosphere using a Hummer 6.2 Sputter Coater (Ladd Research Industries, 
Williston, VT, US). The coater was kept under a high-vacuum evaporator equipped with an omni-
rotary stage tray to help ensure uniform coating. Finally, the images were captured using a JSM-
5600 scanning electron microscope (JEOL USA, Inc., Waterford, VA, US) at an accelerating 
voltage of 5 kV. The samples were evaluated at multiple magnifications.  
 
3.3.8 Dry Granulation Flow Property Measurements 
The powder/granulation flow peoperties were measured and assessed in accord with the current 
USP-NF37 guidelines. The bulk volume (Vo) of 25 g of granules was measured in 50 ml of 
graduated glass cylinder. The bulk density (ρb) was calculated using the following equation:  
Bulk density (𝜌𝑏) =
amount of granules weighed (25 g)
bulk volume (𝑉𝑜)
 
The graduated glass cylinder was tapped 100 times and the reduced volume of the granules was 
measured. Tapped density (ρt) was calculated by using the volume of the granules after tapping 
100 times (Vf) using the following equation:   
Tapped density (𝜌𝑡) =  
weight of granulation/powder (25 g)
tapped volume (𝑉𝑓)
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The angle of repose was measured using a funnel method outlined in the USP-NF37. The height of 
the funnel was placed above the horizontal surface such that the upper tip of the resulting cone 
lightly touched the tip of the funnel. The weighed granules were poured freely through the funnel 
onto the horizontal base. The diameter and the height of the cone was measured and the angle of 
repose (θ) was calculated by the following equation, where ‘h’ and ‘r’ are the height and radius of 
the formed cone, respectively:     





3.3.9 Tablet Compression 
The tablets were prepared on a single station tablet press (Globe) using 8.0 mm flat face tooling 
and standard concave tooling. The compression force varied per the experimental design 
requirements in the screening study, which were evaluated at 100, 200 & 300 kg/cm2 in the main 
effects screening study. Compression forces greater than 300 kg/cm2 resulted in formulation 
leakage around the compression tooling. The compression force was held constant in the 
optimization study (200 kg/cm2). 
 
3.3.10 Tablet Properties  
A dual scooping projection Vanderkamp friabilator (Vankel Industries Inc. Chatham, NJ) filled 
with 33 200mg tablets in one side, to meet USP requirements, was used to assess tablet friability. 
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The friabilator was allowed to rotate continuously for four minutes at 25rpm. The tablets were 
accurately weighed prior to the test, and carefully de-dusted and reweighed after the test.  
Tablet hardness was assessed using a Schleuniger hardness tester. Each tablet tested was placed 
firmly against the stationary anvil prior to beginning the test, and all debris from the previous test 
was carefully removed before performing replicate tests (n=10).  
Weight variation was measured on a microbalance. Twenty tablets were weighed, and their 
average determined. The weight of the individual tablets was then compared to the average and 
evaluated within USP specified tolerances for uncoated tablets (± 7.5%). 
 
3.3.11 Dissolution Testing  
The tableted formulations were assessed for in vitro drug release in 900ml gastric media (0.01N 
HCl) using USP apparatus I (Hanson SR8) at 37 ± 0.5°C with a basket rotation speed of 100 rpm 
over a 24 hour period. The dissolution vessels were equipped with UV-Vis fiber optic probes 
(Rainbow Dissolution Monitor, pION) and the detector was set at a wavelength (λMax) of 290nm.
 
 
3.4 Results & Discussion: 
3.4.1 Preliminary Range Finding Studies & Observations 
Prior to utilizing a statistical experimental design, it was necessary to conduct a series of 
prescreening and range finding studies as no prior knowledge was available to suggest appropriate 
formulation and/or operational parameters for this novel process. As would be anticipated, 
observations that are unique to this dry granulating approach were made.  
Figures 3-1a & 3-1b below provide a visual comparison of the in-process materials, and illustrate 
the observed differences between the formation of a typical polymer melt, depicted in Figure 3-
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1a, and a compacted dry mass, Figure 3-1b, of the same composition. It should be noted that 
presence of mixing elements was necessary to provide the compaction forces which resulted in the 
formation of the dry granules. As can be seen in Figure 3-1b, uncompacted powder is metered out 
by the conveying elements and subsequently compacted by the mixing elements, where the 
compact takes on the matte appearance similar to that of a roller compacted ribbon. Discrete 
granules (Figure 3-1b) can be seen along the conveying elements moving beyond this compaction 





Additionally, the ability to easily mill the compact back into a fine powder further indicates that a 
dry agglomerate is being formed. In contrast, the material on the mixing zone in Figure 3-1a has 
Figure 3-1a (Top) and 3-1b (Bottom): Graphic Illustration of the Observed Differences 
between a Polymer Melt on the Mixing Elements (3-1a) and the Compacted Powder Mass 




the glossy appearance that commonly results from the complete melting of polymers. The melted 
mass could not be easily removed, nor crushed back into a fine powder. This is a common 
occurence during HME processes as pharmaceutical polymers tend to have a relatively high 
affinity for metal after achieving a molten state. 
During processing, it was consistently observed that dry powder exited the barrel prior to 
the appearance of granules, indicating that a buildup of back pressure was required to facilitate the 
agglomeration process. This differs from HME processes in that, while the generation of back 
pressure is common with extruders in general, during a melt extrusion or melt granulation process 
agglomerated material typically appears immediately when output is achieved. Additionally, the 
torque values measured during a melt extrusion process tend to become elevated at steady state as 
the polymeric carriers become molten and viscous. On the other hand, during the TSDG process 
the torque values remained exceptionally low with relatively large fluctuations ranging from 0.72-
3.12 Nm. This observation was brought to greater acuity when the optimized formulation was both 
dry granulated and melt extruded with the barrel temperature profile being the only adjusted 
variable. The polymer melt produced consistent torque values of approximately 5.3 Nm. While 
seemingly low, the torque values resulting from the melt process are also a function of the reduced 
feed rate, which were representative of the feed rate employed during the TSDG process.   
 
3.4.2 Twin-Screw Lubrication  
During a melt extrusion process, the melt itself serves as the lubricant for the moving parts during 
processing; however, during a TSDG process this is not the case as no melted material is present. 
During these preliminary studies, observable metal-on-metal contact between the extruder screws 
and barrel frequently occurred. In order to prevent product degradation and/or contamination, as 
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well as damage to the processing equipment itself, it became desirable to incorporate a solid 
lubricant. Similar concerns are commonly addressed during tableting processes by the addition of 
nominal quantities of a solid lubricant such as magnesium stearate or stearic acid. Likewise, the 
addition of magnesium stearate was investigated for the mitigation of these effects. While the 
addition of modest quantities of magnesium stearate (0.2%) eliminated the previously observed 
metal-on-metal noises emanating from the extruder, it was observed that a narrow range of its 
utility existed as the addition of relatively larger quantities (0.5%) resulted in unfavorable 
quantities of fine particles (often greater than 50%). This was attributed to excessive lubrication 
of the powder mass by the magnesium stearate, which, in turn, resulted in decreased compactability 
of the dry mass within the extruder. The addition of even larger quantities (1.0%) frequently 
prevented the formation of granules entirely. Likewise, the method of its addition also produced 
varying effects on the granulating process. More specifically, the addition of magnesium stearate 
into the physical mixture needed to occur during the final stage of blending as earlier addition 
would also prevent granulation. Finally, limiting the quantity of dry lubricant present while 
granulating, and the utter absence of a lubricating melt, required limiting the extruder’s screw 
speed to a maximum of 200 rpm.    
 
3.4.3 Screw Design 
Screw configuration demonstrated profound effects on the process. Figure 3-2a-e illustrates the 
various screw configurations explored during this research. Figure 3-2a shows a configuration that 
is similar to those used in typical polymer processing or HME operations as the numerous mixing 
elements impart considerable shear to the in-process materials. This configuration consistently 
resulted in the formation of a melt material at any appreciable screw speed. On the other hand, the 
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screw design in Figure 3-2b, which consisted of all conveying elements, served to merely pump 





Beginning again with configuration 3-2b, three mixing paddles were added near the discharging 
end of the barrel, which resulted in a third configuration (Figure 3-2c). This configuration was 
capable of yielding granules. From this observation, it was apparent that an alternative approach 
to screw configuration, relative to HME applications, was required to produce a dry granulation. 
Two additional configurations capable of producing granules were developed (Figures 3-2d & 3-
2e). In Figure 3-2d, an additional mixing zone has been added closer to the feeding hopper. The 
Figure 3-2a-e: a: ThermoFisher Preconfigured Screw Design; b: All Conveying Screw 
Design; c: Single Mixing Zone Screw Design; d: Two Mixing Zone Screw Design; e: 




configuration in 3-2e is a modified version of 3-2d where the mixing elements near the discharge 
section of the screw has been altered in order to evaluate effects of mixing element offset angle.  
 
3.4.4 Quality by Design 
In general, QbD studies involve the systematic utilization of various elements and tools (e.g. 
QTPP, Risk Assessment, DoE, etc.). This phase of investigation began with the identification of 
the product’s critical quality attributes (CQAs) in the quality target product profile (QTPP, Table 
1). Based on the predefined CQAs, excipients possessing the critical material attributes (CMAs) 
were selected. In the same fashion, the critical processing parameters were identified and selected 
for further study. Based on these observations, an initial risk assessment (Table 3-2) was performed 
to openly identify the variables perceived to pose that greatest risk to the CQAs. The CMAs & 
CPPs (inputs) were statistically analyzed through the DoE process where variation therein was 
assessed for variations in the CQAs (outputs).  
   
Table 3-2: Initial Risk Assessment 
 
3.4.5 Experimental Designs (DoE) & Analysis 
Prior to implementing the DoE, multiple factors were fixed. For example, the percent of intra-
granular magnesium stearate used to lubricate the powder mixture, as well as the screws, was held 
at constant at 0.2% during the compaction process, while extra-granular magnesium stearate was 





Size Low Low Low 
Assay High Low Low 
Content Uniformity Low High High 
Drug Release High High High 
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held constant at 0.5% for compression purposes. Additionally, it had been previously observed 
that variation in tablet tooling (standard concave vs. flat face) produced no observable variations 
in the tablets physical properties (disintegration, hardness & friability). This was attributed to the 
relatively large quantities of binder in the formulations. All of the polymers that were evaluated 
(ethyl cellulose, hydroxypropyl cellulose & hydroxyethyl cellulose) were capable of producing 
granules using the process and formulation ranges that were employed; however, in order to reduce 
the number of experiments required by a DoE, the subsequent experiments were limited polymeric 
blends consisting of HPC and HEC only.  
 
3.4.6 Main Effects Screening DoE 
A fractional factorial design (Minimum Number of Runs with Resolution IV; Min Run Res IV) 
with two center points was utilized as a screening design in order to determine the main effects 
from the formulation and process variables. The ranges of the responses and their main effects are 
listed in Table 3-3. Crystallinity, hardness and friability were not evaluated during the 
optimization/characterization phase of the DoE as they consistently produced acceptable values 
within the ranges under investigation. Additionally, these ranges would only be further restricted, 









Table 3-3 Main effects assessed by pareto analysis of screening DoE (Min. Run Res. IV). 
Response Range Main Effect 
Crystallinity NA NA (Always Maintained) 
Percent Fines 12 – 49% Polymer Ratio 
Hausner Ratio 1.05 – 1.39 Screw Configuration 
Compressibility Index 4.76 – 28.17 Screw Configuration 
Angle of Repose 22.0 – 38.7 Polymer Ratio 
Tablet Friability 0.0 0.3% Drug Loading 
Tablet Hardness 8.6 – 18.7kp 
Screw Config., Compression 
Force, Drug Loading 
Time to 80% Dissolution 3.0 – 15.3 hr. Polymer Ratio, Drug Loading 
 
 
3.4.7 Tablet Compression  
Initially, tablets were compressed without the addition of extra-granular excipients; however, this 
resulted in the occasionally observed picking and sticking (the adherence of granulated particles 
to the tablet tooling) upon tablet ejection. The addition of 0.5% extra-granular magnesium stearate 
prevented these previously observed failures.  
 
3.4.8 Tablet Properties 
The granules produced in the initial screening design were mixed with and additional 0.5% extra-
granular magnesium stearate and pressed into tablets using the appropriate compression force and 
the same 8mm flat face tooling. These reformulated tablets were assessed for hardness and 
friability (Table 3-4).   
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Table 3-4. Tablet Friability and Hardness Data from the Screening DoE with 
extragranular magnesium stearate. 
Run Order Friability (%) Hardness (kp) 
1 0.05 15.8 
2 0.18 16.0 
3 0.10 15.9 
4 0.10 18.7 
5 0.0 11.5 
6 0.05 12.6 
7 0.15 14.0 
8 0.30 8.6 
9 0.10 13.6 
10 0.05 11.2 
11 0.0 12.1 
12 0.0 11.8 
13 0.0 15.0 
14 0.05 17.3 
15 0.05 13.4 
16 0.15 14.4 
 
 
3.4.9 Characterization DoE 
With the completed main effects/screening design results, which reduced the previously 
investigated six independent variables to three main effects (i.e. screw design, polymer ratio & 
drug loading), a full factorial (23) with four center points (Table 3-5) was created to evaluate 
potential interactions between the main effects, and, ultimately, to predict an optimized 









Table 3-5: 23 Full Factorial with 4 Center Points. Screw Design 1: Figure 2d; Screw Design 
















1 1 3:1 50 13.2 1.3 24.4 12.5 
2 2 1.7:1 42.5 14.0 1.3 25.4 11.5 
3 2 3:1 35 10.5 1.3 22.4 15 
4 2 1:1 35 13.6 1.2 13.5 11.5 
5 1 1.7:1 42.5 13.1 1.3 20.5 14 
6 1 1.7:1 42.5 10.3 1.3 24.4 12 
7 1 1:1 50 17.1 1.3 23.1 8.5 
8 2 1.7:1 42.5 13.2 1.3 24.4 12 
9 2 1:1 50 10.7 1.3 20.3 6.5 
10 1 3:1 35 10.7 1.2 15.6 15 
11 2 3:1 50 12.6 1.2 19.2 11 
12 1 1:1 35 11.0 1.3 22.5 8 
 
 
The parameters that did not produce main effects in the screening design (i.e. screw-speed, feed 
rate & tablet compression force) were presumed to have ngelible effects relative to the main effects 
and, as such, the mean of their previously utilized ranges was taken and implemented in the 
characterization study at fixed values. Therefore, the extruder’s feeder output was set to 4g/min 
(previous range: 3-5g/min.), the screw speed was maintained at 150rpm (previous range: 100-200 
rpm), and the tablet compression force was held constant at 200kg/cm2 (previous range: 100-300 
kg/cm2) . The barrel temperature was held at 65oC from zones 2 until granule discharge. The 
responses, their statistically significant main effects and interactions are summarized in Table 3-6 







Table 3-6: Response Ranges and Statistically Significant Main Effects & Interactions from 
the Characterization DoE. 
Response Range Interaction Type and/or Main Effect(s) 
Percent Fines 10.3 – 17.1 
Polymer Ratio & Drug Loading (Main Effects); 
Interaction with Screw Design 
Hausner Ratio 1.2 – 1.3 
Screw-Configuration, Polymer Ratio & Drug 
Loading (3-Way Interaction) 
Compressibility 
Index 
13.5 – 25.4 
Polymer Ratio & Screw Configuration (Main Effects 
& Two Way Interaction) 
Angle of Repose 33.7 – 42.0 Insufficient Variation Within the Model 
Time to 80% 
Dissolution (hr.) 
6.5 - 15 
Polymer Ratio & Drug Loading (Independent Main 
Effects; Interaction with Screw Configuration) 
 
3.4.10 Percent Fines 
The following values were used in the analysis of variance (ANOVA) of the “percent fines” 
response variable. A Model F value of 14.64 in the unadjusted model suggests that the model is 
significant. The “Lack of Fit F-Value” 0.75 indicates that the lack of fit is not significant (p > 
0.0011). The model is statisitically significant for the response Percent Fines with an “R-Squared” 
value of 0.7262. The Predicted R-Squared value (0.430) is in reasonable agreement with the 
Adjusted R-Squared value (0.5698). The adequacy/precision ratio of 7.697 indicates an adequate 
signal. This model can be used to navigate the design space. The following polynomial equation, 
which is expressed in terms of coded factors, was generated for the mathematical description of 
percent fines generated during granulation: Percent Fines = +12.49 -0.67*B –0.98*C -1.18*A*C; 
where A, B and C are the screw configuration, polymer ratio and drug loaing respectively. In this 
equation, a positive or negative sign prior to a coded variables coefficient is inversely related to an 
additive or deleterious effect respectively as the response variable is a measure in increasing in-
process fine material. In this case, an decrease in the polymer ratio, which corresponds to a 
decrease in the high molecular weight binder (HPC HF), corresponds to a increase in fine material, 
where an increase in drug content corresponds to decrease in fine materials. The above equation is 
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graphically depicted by both a contour plot and response surface for a visual assessment of these 
variables (Figure 3-3). 
 
 
Figure 3-3: Percent Fines contour plot and response surface graph with Screw Design 1 
(Figure 3-2 d). 
 
3.4.11 Hausner Ratio 
The Hausner Ratio of the granules was evaluated using the procedure outlined by the USP-
NF37. The full factorial experiments resulted in the range of values of 1.16 – 1.34, which, while 
satisfying the compendial specifications spanning “Good” to “Passable”, did not produce sufficient 
variation to result in a predictive model (Model F value 1.13, Predicted R2 -2.27). Given these 
results, the values for the Hausner ratio were not used to produce a predictive equation. Instead, 
given that the entire range of values was acceptable, the span of the data points was taken and 







The following values were used in the analysis of variance (ANOVA) of the “compressability” 
response variable. A Model F value of 7.24 in the unadjusted model suggests that the model is 
significant. The “Lack of Fit F-Value” 0.70 indicates that the lack of fit is not significant (p > 
0.01114). The model is statisitically significant for the response Percent Fines with an “R-Squared” 
value of 0.7308. The Predicted R-Squared value (0.4679) is in reasonable agreement with the 
Adjusted R-Squared value (0.6299). The adequacy/precision ratio of 6.545 indicates an adequate 
signal. This model can be used to navigate the design space. The following polynomial equation, 
which is expressed in terms of coded factors, was generated for the mathematical description of 
compressability of the granulation: Compressability = +22.08 +1.25*A –1.50*B +0.5*C -
1.50*AB; where A, B and C are the screw configuration and polymer ratio and drug loaing 
respectively.   
 
Figure 3-4: Compressibility contour plot and response surface graph with screw design 1 





3.4.13 Angle of Repose 
The flowability of the granules was evaluated using the Recommended Procedure for Angle of 
Repose outlined by the USP-NF [86]. The full factorial experiments resulted in the range of values 
presented in (33.7 – 42.0), which produced insufficient variation to result in a sufficiently 
predictive model. However, this range of values falls within the qualitatively described ranges for 
angle of repose in the USP-NF [86]. More specifically, the range presented spans what the USP 
describes as “Good” to “Fair”. Given these results, the values for the angle of repose were not used 
to produce a predictive equation. Instead, given that the entire range of values was acceptable, the 
mean of the data points was taken and utilized to inform numerically predicted solution. 
 
3.4.14 Time to 80% Dissolution 
The in-vitro drug release was assessed using the conditions outlined for this drug by the FDA [87].  
The following values were used in the analysis of variance (ANOVA) of the dissolution predictive 
model. A Model F value of 14.67 in the unadjusted model suggests that the model is significant. 
The “Lack of Fit F-Value” 2.20 indicates that the lack of fit is not significant (p > 0.0011). The 
model is statisitically significant for the response Time to 80% Dissolution with an “R-Squared” 
value of 0.7653. The Predicted R-Squared value (0.5668) is in reasonable agreement with the 
Adjusted R-Squared value (0.7131). The adequacy/precision ratio of 10.468 indicates an adequate 
signal. This model can be used to navigate the design space. The following polynomial equation, 
which is expressed int terms of coded factors, was generated for the mathematical description of 
tablet dissolution: Time to 80% Dissolution = +11.46 +2.37*B –1.38*C; where B and C are the 
polymer ratio and drug loaing respectively. In this equation, a positive or negative sign prior to a 
coded variables coefficient is indicative of an additive or deleterious effect respectively. In this 
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case, an increase in the polymer ratio, which represents and increase in the high molecular weight 
polymer (HPC HF), corresponds to prolonging dissolution. Likewise, a decrease in drug content 
also corresponds to an increase the time it takes to reach 80% dissolution.   As might be anticipated 
when employing a high molecular weight polymer and a BCS I API, an increase in the amount of 
the high molecular weight polymer was correlated with an increase in dissolution time (indicated 
by the “+” symbol in the equation), while an increase in drug loading was correlated with a 
decrease in dissolution time (indicated by the “–“ symbol in the equation). This equation is 
graphically depicted by both a contour plot and response surface for a visual assessment of these 




Figure 3-5: Time to 80% Dissolution Contour plot and Response surface graph with Screw 
Design 1 (Figure 3-2 e) 
 
As might be anticipated when employing a high molecular weight polymer and a BCS I API, an 
increase in the amount of the high molecular weight polymer was correlated with an increase in 
dissolution time (indicated by the “+” symbol in the equation), while an increase in drug loading 
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was correlated with a decrease in dissolution time (indicated by the “–“ symbol in the equation). 
This equation is graphically depicted by both a contour plot and response surface for a visual 
assessment of these variables (Figure 3-5).  
   
 
3.4.15 Fourier Transform Infrared Spectroscopy (FT-IR) 
FT-IR spectral analysis (Figure 3) clearly illustrates the differences between the crystalline and 
amorphous phases of Sildenafil Citrate. As would be expected, the amorphous phase exhibits 
shifted, shorter and broader spectral bands relative to the crystalline phase. These alterations in 
spectral responses arise from the lack of long range order that is characteristic of the amorphous 
phase. This allows for the identification of the API’s post-processing physical phase, which 
demonstrates that the API is still crystalline. Interestingly, the physical mixture shows the carbonyl 
in Sildenafil Citrate, which is centered at 1697cm-1, in the same position as the carbonyl in the 
pure crystalline spectrum, whereas the dry granulated carbonyl is centered at 1699cm-1. While 
there is obviously a spectral shift occurring, it is shifted in the opposite direction of the carbonyl 
in the amorphous phase. This may be indicative of hydrogen bonding between the carbonyl in 
crystalline Sildenafil Citrate and the hydroxyls (ranging from approximately 3600-3200cm-1) 
present in the polymeric carrier(s), which, considering their relative proportions within the 
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Figure 3-6: Mid-Infrared Spectral Evaluation of Sildenafil Citrate’s Post Processing 




3.4.16 Scanning Electron Microscopy (SEM) 
Figure 3-7a through 3-7d illustrates the visually observable differences in the surface morphology 
between the physical mixture, the dry granules and the hot-melt granules, respectively. These 
samples are representative of the optimized formulation predicted by the full factorial model. In 
Figure 3-7a it can be observed that the dry granulated material appears to be a compacted 
agglomerate of the physical mixture presented in Figure 3-7b. The image of the Hot-Melt 
Granulated material in Figure 3-7c appears homogenous and lacks the observable appearance of 
its constituents. Further magnification of the Hot-Melt Granulated material revealed no additional 
information; however, Figure 3-7d, taken at 300X magnification, demonstrates that compacted 







3.4.17 Numeric Prediction of Optimization & Confirmation 
The full factorial model was used to predict a set of graphically and numerically optimized 
formulations (Table 3-7). The criteria for the optimization process were based on the CQAs in the 
QTPP as well as the acceptable ranges for the measured responses found in the USP. With a 
Figure 3-7A-D: 4A Physical Mixture (100X), 4B Hot-Melt Granule (100X), 4C Dry 




relatively broad range of acceptability for the dissolution profile (80% in 12 – 18 hrs.), the target 
was set to the median value (15 hrs.). The percentage of fines was set to a range of 10 – 15%, as 
this is the generally acceptable . The lower limit of the Hausner Ratio was set to the lowest value 
obtained during this study (1.15) and the upper limit was set to 1.25 as the USP defines this as the 
cutoff “Fair” flowability. The range for the angle of repose was set such that it encompassed the 
lowest value attained in this study  
Of the most desirable predicted solutions to the predefined ranges and targets, solution 1 was 
selected as it incorporated the highest drug loading, which was one of the primary objectives of 
this research, and it possessed the most favorable desirability value (0.558). The predicted values 
of the proposed formulation and process were then compared to the measured values in during 
confirmation stage of optimization. The measured values are presented in Table 3-7. 
 
Table 3-7: Numerically predicted formulation and process parameters resulting from the 
input acceptable ranges on screw design 1; Confirmation: Confirmatory Results from 





















1 3:1 42.7 11.85 1.25 19.70 13.82 39 0.558 
2 3:1 42.6 11.82 1.25 19.63 13.84 39 0.552 
Confirmation 3:1 42.7 12.05 1.22 21.1 14 36 NA 
 
Based on the desired input model criteria for the individual independent and dependent variables, 
the resulting individual desirability values are graphically depicted in Figure 3-8. While the criteria 
for both the independent variable “drug loading” and the dependent variable dissolution were each 
given the highest priority of the model variables, which are consistent with the product criteria 
established in the QTPP, it can be seen that their respective desirability values lie well below that 
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of the other responses. This is clearly explained by the inversive relationship between the two 
variables, that is, the time required to reach 80% dissolution decreases as drug loading increases 
and vice versa, and equal priority having been given to both. As such, a balance, or compromise, 
between the two criteria was established by the resulting model.   
The overall desirability contour plot and response surface (Figure 3-9) was for predicted 
solution 1 (Table 3-7) was constructed to graphically depict the complete relationship between the 
independent variables and predefined and prioritized response value ranges. Addtionally, these 
plots serve to illustrate that an optimal region of overlap is predicted to exist. It is important to 
note that while the range for desirability is predefined from 0.0 – 1.0, that the obtained value 
(0.558) is a multiplicative mean rather than additive mean, which is to say that if any value were 
unable to meet the input specifications, the desirability function would become 0.0. Therefore, it 
is the existence of some appreciable value greater than 0.0 that is of importance here, which 
justifies proceeding with predicted solution confirmatory experiment (Table 3-7).  
 
 




Figure 3-9: Desirability function contour plot and corresponding response surface. 
 
3.4.18 Design Space 
When attempting to optimize for multiple variables, it is necessary to find the region where all 
requirements are met simultaneously. The close agreement of the Predicted Solution values with 
the values collected from the confirmation experiment (Table 3-7) suggest the suitability of the 
predictive model. As such, the previous contour plots (Figures 3-3, 3-4 & 3-5) have been 
superimposed to produce the overlay plot  in Figure 3-10. This overlay is representative of what is 
considered to be the design space, shaded in blue, where the control space being chosen a subset 
thereof. It can be seen from the plot that the most limiting of the response (dependent) variables 
were the lower boundry condition set for percent fines (10 -15%) and the upper boundry condition 
set for Hausner’s Ratio (1.34). The compressibility index and angle of repose, within the ranges 





Figure 3-10: Overlay plot of the resulting design space.  
 
3.5 Conclusion 
This study explores the previously unreported applicability of a fully intermeshing co-rotating 
twin-screw extruder for the production of dry granules. Fundamental differences from 
conventional HME processing were discovered and assessed accordingly. Screw design played an 
integral role in the formation of the granules, while the extruder feed rate was limited by the 
absence of a lubricating polymer melt. Utilizing the QbD methodology to investigate this 











THE EFFECT OF MIXING BLOCK OFFSET ANGLE ON THE DISTRIBUTION OF 
CARBAMEZAPINE AND CAFFEINE CITRATE IN A POLYMERIC MATRIX  
4.1 Introduction 
While screw configuration is widely regarded as a critical processing parameter in extrusion 
processes, as it plays a vital role in the physicochemical characteristics of the final extrudates, little 
practical information is available in the literature concerning the effects of screw configuration on 
pharmaceutical formulations. Moreover, nearly all of that information is focused on the conversion 
of a crystalline API into its amorphous form with little attention given to the intermediate changes 
that occur during processing. To some extent this stands to reason as the initial obstacles that HME 
was investigated to address were related to the poor aqueous solubility of many newer APIs. 
However, given the numerous processing advanteges that this platform offers, it is well poised to 
serve as an alternative to many more conventional pharmaceutical processing technologies. 
Moreover, this particular platform readily embraces the agency’s current thinking on 
pharmaceutical regualtory matters; namely continuous processing. Given some of the additional 
advantages inherent in HME processing (i.e. , fewer processing steps, simple scalability, avoidance 
of organic solvents, etc.), it becomes apparent that processing any suitable API by this technique 
is an attractive option regardless of which BCS class it belongs to. However, in the case of BCS 
class I and class III APIs, where the formation of an API’s amorphous phase might not be desirable, 
it may be appropriate to preserve the initial crystalline structure as solubility enhancement is not 
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necessary and common stability issues associated with amorphous forms, such as recrystallization 
into an undesired polymorphic form, can be avoided. Conversely, a complete understanding of the 
morphological changes that are induced in such an environment poses the possibility controlled 
conversion between polymorphs in situ, much like conversion from a crystalline lattice to a 
molecular or amorphous dispersion is peformed today. The objective of this study is to evaluate 
the effects of screw configuration on active pharmaceutical ingredient (API) morphology using a 
fully intermeshing co-rotating twin-screw extruder and FT-IR chemical imaging for spatial 
determinations. Here the examination takes place within the mixing zones along the co-rotating 
screw.  
 
4.2 Materials & Methods 
Eudragit E PO was generously donated by Evonik (Somerset, NJ.). Carbamezapine and Caffeine 
Citrate were  donated by Ashland Specialty Ingredients (Wilmington, DE).  
 
4.3 Hot-Melt Extrusion  
4.3.1 Thermo Gravimetric Analysis (TGA) 
Prior to melt extrusion processing, TGA (Pyris 1 TGA Perkin Elmer) was utilized to determine the 
thermal stability of the individual polymers and API. Binary mixtures (1:1 w/w) of the individual 
polymers with the API were examined at the temperatures required for melt extrusion processing. 
During TGA, each of the weighed samples was heated from 25oC to 180oC at a rate of 20oC/min. 
in a platinum pan under an inert nitrogen atmosphere purge of 20ml per minute. The samples were 
held at 180oC for 5 minutes to simulate the thermal stresses and residence time encountered during 




4.3.2 Differential Scanning Calorimetry (DSC)   
DSC (Diamond DSC, Perkin Elmer) was utilized to confirm the thermal stability of replicate TGA 
samples. The samples, weighing 4-5 mg each, were placed in hermetically sealed aluminum pans 
and placed under an inert nitrogen atmosphere at a purge rate of 20ml per minute. These samples 
were heated from 25oC to 180oC at a rate of 20oC/min., held at 180oC for 5min. and cooled to room 
temperature. The thermograms of these samples were analyzed for deviations from the 
thermograms of the pure substance and other significant thermal events. Calibration of the 
instrument was performed with an Indium reference.  
 
4.3.3 Hot-Melt Extrusion Processing 
Prior to HME processing, the polymer was sieved with a USP #35 mesh screen to remove any 
aggregated particles. The compounds required for each physical mixture were placed in a V-shell 
blender (GlobePharma, Maxiblend®) and mixed at 20 rpm for 20 minutes. A fully intermeshing 
co-rotating twin-screw extruder (11 mm Process 11, ThermoFisher Scientific) was used to process 
the physical mixtures.  
 
4.3.4 FT-IR & Mid-Infrared Chemical Imaging 
Mid-infrared spectral analysis was conducted on an FT-IR bench (Agilent Technologies Cary 660, 
Santa Clara, CA.). The bench was equipped with an ATR (Pike Technologies MIRacle ATR, 
Madison, WI), which was fitted with a single bounce diamond coated ZnSe internal reflection 
element. Chemical imaging was conducted using an infrared microscope (Agilent Technologies 
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Cary 620 IR, Santa Clara, CA.) equipped with a 64 x 64 pixel focal  plane array (FPA) with a 
germanium micro-ATR.  
 
4.4 Results and Dsicussion  
4.4.1 Thermogravimetric Analysis 
No thermal events were noted during thermogravimetric analysis of the binary mixtures during 
the course of this study, which is indicative of thermal stability over the temperature ranges 
utilized.  
4.4.2 Hot-Melt Extrusion Processing 
The barrel temperature profile and screw speed were based on the physical properties of polymeric 
carrier in each of the preliminary physical mixtures and a 2mm rod die was attached to the end of 
the barrel. After allowing the extruder to reach a steady state, a barrel plug was removed from the 
top half of the barrel, which exposed the respective mixing zones, and samples were collected 
directly from the mixing elements for analysis. The samples were either immediately analyzed, or 
stored in foil lined polyethylene bags for future analysis. Three screw configurations. Each screw 
design was characterized by three consecutive mixing blocks. Each block was composed of mixing 
paddles with offset angles of 30o or  90o each. It is important to note that these angles were not 
investigated in conjunction with eachother, but were examined for the individual angle effects on 






4.4.3 FT-IR & Mid-Infrared Chemical Imaging 
A qualitative examination of the FTIR spectrum for each of compounds indicates that there 
exists a region of clear spectral resolution for each of the model drugs within the polymer matrix 
(Figure 4-1).  
 
Figure 4-1: FT-IR spectra of Eudragit E PO (EPO), Carbamezapine (CBZ) and Caffeine 
Citrate (CC). 
More specifically, for the mixture of caffeine citrate (CC) and Eudragit E PO (EPO), CC 
exhibits a very strong peak at 1642cm-1 while EPO presents only baseline contributions in this 





Figure 4-2: FT-IR spectral overlay of Eudragit E PO (EPO) and Caffeine Citrate (CC). 
Here it can be seen that while a marginal contribution to the IR spectrum results from EPO 
(approximately 0.02 AU) at 1642cm-1 the majority of the signal (approximately 0.28 AU) is from 
CC, which allows this peak to be used for spectral imaging. Likewise for the combinations of 
Carbamezapine (CBZ) and EPO, there is a clear contribution to the IR spectrum from CBZ at 
1593cm-1 (approximately 0.22 AU) where EPO again presents only baseline contributions 












Figure 4-3: FT-IR spectral overlay of Eudragit E PO (EPO) and Carbamezapine (CBZ).  
 
Using these clear distinctions in the spectra allows for the generation of resolved chemical 
images such as those in Figure 4-4. Here it can be seen that as the in-process melt travels along the 
mixing block that the active (depicted as a function of intensity for the characteristic peak; 1642cm-
1) is not being distributed thoughout the matrix as intensely as it is being dispersed into smaller 
units within a given area, that is, the blue area that is representative of the absence of this peak is 
slowly disappearing while the rea areas are declining in intensity. Interestingly, the corresponding 
DSC thermograms for each of the three regions sampled showed practically no difference in AUC 
as the in-process material passed through the mxing zone (1.23, 1.23 & 1.14 J/g, respectively) 
indicating that though the material is being dispersed, it has not yet been converted from its 





Figure 4-4: IR chemical images take of CC from the Beginning, Middle and End of 
Mixing zone. 
 
The opposite can be determined from the behavior of CC in EPO when the mixing element angles 
are chaged to 90o (Figure 4-5). Here we can see that the orientation of the mixing elements is 
imparting more distributive character to the in-process material as the intensity of the signal from 















Figure 4-6: IR chemical images take of CBZ from the Beginning, Middle and End of 
Mixing zone. 
In Figure 4-6 it can be seen that CBZ is undergoing dispersive mxing similar to that of CC in 
Figure 4-4. The DSC data supports this also as the AUC values are relatively unchanged (3.2, 3.0 
& 2.6 J/g), again indicating that the dispersive mixing being imparted to the in-process material 




Figure 4-7: IR chemical images take of CBZ from the Beginning, Middle and End of 
Mixing zone. 
Figure 4-7 shows that CBZ is being distributed thoughout the matrix as would be expected from 
perpendicular mixing elements; however, the DSC data indicates that that more material is 
undergoing amorphous conversion due, in part, to the intense deformations imparted as the 
polymer melt is divided and recombined (AUC 1.3, 0.68 and 0.68 J/g respectively). Despite the 
conventional knowledge that perpendicular are primarily responsible for distributive mixing, it 







FT-IR spectral imaging could be a useful offline tool for the investigation of the relationship 
between screw configuration and API distribution/dispersion within a polymer matrix. It is worth 
noting that only realtively simple missing blocks were examined in this study and far more 
complex designs are commonly employed during a typical Hot-Melt Extrusion process. This in 
combination with the effects noted here, namely the loss of crystallinity in the CBZ samples, 
may indicate that particular formulations are more or less sensitive to the stresses imparted by 






















SUMMARY & CONCLUSIONS 
In chapter 2, the use of an extruded intermediate was investigated in a somewhat novel 
sense (i.e. maintaining the API crystallinity) while approaching subsequent product development 
from a more conventional prospective. Here it was noted that care must be taken to ensure the 
physical identity of an API crystalline lattice. Additionally, incorporating milled extrudates into 
oral solid dosage forms poses interesting challenges due to the large differences in density as 
opposed to particle size. Chapter 3 explores the previously unreported use of a twin-screw extruder 
for the production of a dry granulation using quality by design principles. This study, in tandem 
with another study by a colleague, represents the first of its kind as no prior art could be found. 
Here the use of a twin-screw extruder is explored as an alternative dry granulating technology. 
Chapter 4 is an attempt to take a more granular look into the effects of screw design by examining 
the effect of paddle offset angle on dispersion and distribution of two APIs within a polymer 
matrix. This, in tandem with DSC data for phase identification, produced both anticipated (as in 
the case of caffeine citrate) and unanticipated results (demonstrated by carbamezapine).   
The underlying theme of the research performed in order to arrive at this dissertation is simple; 
investigations into twin-screw extruder screw configuration. More broadly, this work investigates 
the interplay between a formulation’s constituents and the extruder that is processing them. At the 
time that this research was conducted, the current pharmaceutical literature concerning screw-
configuration seemed to regard it as more of an art rather than a science. On the other hand, the 
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information available from food, metals, ceramics, engineering literature approached screw 
geometry from a predominately mathematical perspective. In the current, neither of these 
approaches work well. Until mathematical based simulation models are more fully matured, the 
topic of screw configuration, and extrusion in general, should be treated with a combination of 
theory and practical experience. Finally, while the melt extrusion process is completely amenable 
to the FDA’s push toward the QbD paradigm shift, some understanding and flexibility will be 
required on the agency’s end to fully realize this processing technology. More specifically, the 
quantities listed in the Inactive Ingredient Database (IID) are simply insufficient to fully implement 
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